<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387517</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2333</org_study_id>
    <nct_id>NCT00387517</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy of Combo Therapy With Aliskiren &amp; Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension</brief_title>
  <official_title>An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and efficacy of combination therapy of
      aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in
      patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sitting diastolic blood pressure lowering effect at baseline, and week 8.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean sitting systolic blood pressure (msDBP) lowering from baseline to week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a blood pressure control target at week 8</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">726</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren/HCTZ</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients 18 years old or older.

          -  Patients with a diagnosis of hypertension defined as follows:

               -  Newly diagnosed patients or patients who have not been treated for hypertension
                  within the 4 weeks prior to Visit 1 must have a msDBP &gt;= mmHg and &lt; 110 mmHg at
                  Visit 1.

               -  All patients who have been treated for hypertension within the 4 weeks prior to
                  Visit 1 must have a msDBP &gt;= 85 mmHg and &lt; 110 mmHg at Visit 2.

               -  All patients must have a msDBP &gt;= 90 mmHg and &lt; 110 mmHg at Visit 5.

          -  Patients who are eligible and consent to participate in the study

        Exclusion Criteria:

          -  Severe hypertension (msDBP &gt;= 110 mmHg and/or MSSBP &gt;=180 mmHg).

          -  Previous or current diagnosis of heart failure.

          -  History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic
             cerebral attack, myocardial infarction, coronary bypass surgery, or any percutaneous
             coronary intervention.

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2531</url>
    <description>Results for CSPP100A2333 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Blumenstein M, Romaszko J, Calder√≥n A, Andersen K, Ibram G, Liu Z, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin. 2009 Apr;25(4):903-10. doi: 10.1185/03007990902804158 .</citation>
    <PMID>19245300</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Diastolic</keyword>
  <keyword>systolic</keyword>
  <keyword>hypertension</keyword>
  <keyword>aliskiren</keyword>
  <keyword>blood pressure</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>HCTZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

